Core Insights - The inclusion of neffy on Express Scripts' commercial formularies enhances access to life-saving allergy treatment for patients managing Type 1 allergic reactions, including anaphylaxis [1][3] - neffy is the first FDA-approved epinephrine nasal spray, providing a needle-free alternative to traditional injectables, and is designed for rapid administration [2][5] - ARS Pharmaceuticals anticipates that other payers will follow Express Scripts in providing access to neffy, further expanding its market reach [3] Product Information - neffy 2 mg is indicated for emergency treatment of Type I allergic reactions in patients weighing 30 kg or greater, including both adults and children [2][5] - The product features a shelf-life of 30 months and can withstand temperatures up to 122 degrees Fahrenheit, making it portable and user-friendly [2] - neffy addresses limitations associated with epinephrine autoinjectors, such as fear of needles and complexity, which can lead to delays in treatment during emergencies [15] Market Context - Approximately 40 million people in the U.S. experience Type I allergic reactions, with around 20 million diagnosed and treated for severe reactions in the last three years [15] - Despite the high number of patients, only 3.2 million filled their active epinephrine autoinjector prescriptions in 2023, indicating a significant market opportunity for neffy [15] - The quick turnaround from product introduction to inclusion in formularies (nine weeks) demonstrates the demand and potential for neffy in the market [3]

Company Overview - ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering at-risk patients and caregivers to protect against severe allergic reactions that may lead to anaphylaxis [3] - The company is commercializing neffy® 2 mg (trade name EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [3] Upcoming Events - ARS Pharmaceuticals will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco [1] - Richard Lowenthal, Co-Founder, President and CEO, will present on January 15, 2025, at 7:30 a.m. PT, and management will engage in one-on-one meetings with investors [2] - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days [2]

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that its licensing partners in China, Japan and Australia have filed for approval of neffy® (epinephrine nasal spray) 2 mg in their respective countries. neffy 2 mg was recently approved in the U.S. for the treatment of Type I Allergic Reac ...

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to emp ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.13, delivering a surprise of -8.33%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) | --- | --- | |---------------------- ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royaltiesWell-capitalized with $349.6 million in cash, cash equivalents and short ...

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.In August, the FDA approved ARS Pharmaceuticals’ Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients.Neffy is a ...

Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 10.4% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.67 indicates a potential upside of 67.6%.The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $22 indicates a 43.6% increase fr ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting the need for strong fundamentals and positive earnings revisions to maintain momentum [1][2]. Group 1: Stock Performance - ARS Pharmaceuticals, Inc. (SPRY) has shown a solid price increase of 55.1% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 4.9% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, SPRY is trading at 86.1% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - SPRY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like SPRY that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help in finding winning stock picks [8].